An Open-label, Comparative, Randomized, Multicenter Phase IV Clinical Study to Investigate the Clinical Efficacy and Safety of the Drug Ranquilon, Tablets, 1 mg, in Patients With Anxiety Disorders Due to Neurasthenia and Adaptation Disorders
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Ranquilon (Primary) ; Afobazol
- Indications Anxiety disorders
- Focus Therapeutic Use
- Sponsors Valenta Pharmaceuticals
Most Recent Events
- 04 Mar 2025 New trial record